Clinical Trials | December 30, 2025
Biohaven reports Phase 2 depression trial results
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Harbour BioMed brings advanced antibody discovery platforms to the table
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
HYMPAVZI’s safety profile was generally favorable
Subscribe To Our Newsletter & Stay Updated
